Michaela Tsai, MD, Oncology, Minneapolis, MN, Abbott Northwestern Hospital

MichaelaLTsaiMD

Oncology Minneapolis, MN

Hematologic Oncology

Physician

Dr. Tsai is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Tsai's full profile

Already have an account?

Education & Training

  • Harvard Medical School
    Harvard Medical SchoolClass of 1998
  • Duke UniversityBS, Chemistry and Religion, Summa Cum Laude, 1990 - 1994

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 2000 - 2021
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Why Is Cancer Genetic Counseling Underutilized by Women Identified as at Risk for Hereditary Breast Cancer? Patient Perceptions of Barriers Following a Referral Letter  
    Alyssa Kne, Heather Zierhut, Michaela L Tsai, Journal of Genetic Counseling

Abstracts/Posters

  • Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDA...
    Michaela L. Tsai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • 70-Gene Signature Impacts Treatment Decisions in Breast CA
    70-Gene Signature Impacts Treatment Decisions in Breast CAOctober 29th, 2017
  • New Data Shows Agendia’s MammaPrint® Can Prevent Under and over Treatment of Breast Cancer Patients with an Intermediate/Indeterminate OncotypeDx Recurrence Score
    New Data Shows Agendia’s MammaPrint® Can Prevent Under and over Treatment of Breast Cancer Patients with an Intermediate/Indeterminate OncotypeDx Recurrence ScoreJune 7th, 2016
  • Agendia Appoints Dr. Gabriel Hortobagyi as Chairman to Their Medical Advisory Board
    Agendia Appoints Dr. Gabriel Hortobagyi as Chairman to Their Medical Advisory BoardJune 1st, 2016

Hospital Affiliations